Open Access. Powered by Scholars. Published by Universities.®
Organismal Biological Physiology Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- Adding tools (1)
- Antibodies (1)
- Biologics (1)
- Bulk tissues (1)
- C (1)
-
- CRSwNP (1)
- Chronic disease/drug therapy (1)
- Chronic rhinosinusitis with nasal polyposis (1)
- Clinical trials (1)
- Compound-specific analyses (1)
- Depemokimab (1)
- Eosinophil (1)
- Eosinophils/drug effects (1)
- H (1)
- Humanized/administration & dosage/pharmacokinetics/adverse effects/therapeutic use (1)
- Humans (1)
- II-5 (1)
- Interleukin-5 (1)
- Interleukin-5/antagonists & inhibitors (1)
- Mepolizumab (1)
- Metabolic routing (1)
- Metabolism (1)
- Monoclonal (1)
- N (1)
- Nasal polyps/drug therapy/complications (1)
- O (1)
- Origins of nutrients (1)
- Phase III as topic (1)
- Rhinosinusitis/drug therapy/complications (1)
- S (1)
Articles 1 - 2 of 2
Full-Text Articles in Organismal Biological Physiology
Depemokimab: A Twice Yearly Anti-Il 5 Biologic For Chronic Rhinosinusitis With Nasal Polyps (Crswnp) - A Narrative Review, Marn Joon Park, Joseph K. Han, Kent K. Lam
Depemokimab: A Twice Yearly Anti-Il 5 Biologic For Chronic Rhinosinusitis With Nasal Polyps (Crswnp) - A Narrative Review, Marn Joon Park, Joseph K. Han, Kent K. Lam
Department of Otolaryngology (ENT) Faculty Publications
Depemokimab is a monoclonal antibody that targets interleukin-5 with enhanced binding affinity and an extended terminal elimination half‑life of 6-8 weeks. The unique pharmacodynamic features of depemokimab enable sustained suppression of type 2 inflammation with twice‑yearly subcutaneous dosing. This narrative review provides details of depemokimab's molecular profile, pharmacokinetics, and pharmacodynamics and results regarding the clinical efficacy and safety of depemokimab from recently published Phase 3 clinical trials for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). In 528 severe adult CRSwNP patients (ANCHOR‑1/‑2 trials), depemokimab achieved Δ total endoscopic nasal polyp score by -0.70 (p < .001) and Δ nasal obstruction verbal response scale by -0.24 (p = .003) at week 52, compared to placebo. Twice‑yearly 100 mg depemokimab provides durable eosinophil suppression and with a safety profile comparable to placebo in Phase 3 trials for CRSwNP. Future work should refine biomarkers and assess comparative cost‑effectiveness and long‑term adherence, safety, and effectiveness.
Editorial: New Frontiers In The Application Of Stable Isotopes To Ecological And Ecophysiological Research, Keith A. Hobson, John P. Whiteman, Seth D. Newsome
Editorial: New Frontiers In The Application Of Stable Isotopes To Ecological And Ecophysiological Research, Keith A. Hobson, John P. Whiteman, Seth D. Newsome
Biological Sciences Faculty Publications
No abstract provided.